• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Familial hypercholesterolaemia

Familial hypercholesterolaemia: identification and management

Status:	History
Publication date:	August 2008
Wave:	9
Process:	CG
Topic area: Endocrine, nutritional and metabolic

Project team | Schedule | Project history | Key documents

 

NICE project team

Centre for clinical practice lead:	Gillian Leng
Communications manager:	Adrian Ward
Guidelines commissioning manager:	Sarah Willett
Guidelines coordinator:	Andew Gyton
Patient involvement lead:	Victoria Thomas
Lead collaborating centre:	The National Collaborating Centre for Primary Care
Guidance developer contact:	Nancy Turnbull
Guidelines Development Group:	The Guideline Development Group (GDG) oversees the development process.

Top

Email enquiries

If you have any queries please email nice@nice.org.uk

Top

 

Provisional schedule

Scoping workshop:	17 July 2006
Consultation on draft scope with stakeholders:	10 July - 7 August 2006
Consultation on draft guideline with stakeholders:	11 February - 7 April 2008
Pre-publication check:	TBC
Publication date:	August 2008

Top

 

Project history

Date Update 24 December 2003 The remit (see link below) was received from the Department of Health and the Welsh Assembly Government in October 2003 as part of the Institute's 9th wave work programme. 5 April 2004 Patient Involvement Lead added. 24 August 2004 Executive lead updated. 10 July 2006 The draft scope (see link below) is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed above, by the deadline shown. 8 September 2006 Guidelines Coordinator changed to Bijal Chandarana 4 December 2006 List of stakeholders updated. 10 January 2007 Communications manager changed 11 January 2007 Expected date of issue changed to August 2008 1 February 2007 GDG membership list added. 8 February 2007 The scope (see link below) defines what aspects of care are covered by the guideline and to whom it applies. 13 February 2007 Table of comments on the draft scope published 15 July 2008 It was stated in the initial scope that TA94: Statins for the prevention of cardiovascular disease would be incorporated. It was found that the TA was not relevant to the FH population covered in the guideline. The scope has been amended.

Top

 

Key documents

Familial hypercholesterolaemia: draft consultation comments 27 August 2008 Familial hypercholesterolaemia: list of stakeholders 24 July 2008 Familial hypercholesterolaemia: draft scope 15 July 2008 Familial hypercholesterolaemia: GDG minutes 10 July 2008 Familial hypercholesterolaemia: consultation 07 February 2008 Familial hypercholesterolaemia: comments on draft scope 13 February 2007 Familial hypercholesterolaemia: final scope 08 February 2007 Familial hypercholesterolaemia: GDG membership 01 February 2007 Familial Hypercholesterolaemia: Draft Scope, comments form 10 July 2006 Familial hypercholesterolaemia: remit 23 December 2003 Guideline Development Process - Information for Stakeholders 14 January 2002 National Collaborating Centre for Primary Care 02 June 2003 Stakeholder registration 21 April 2004 The guideline development process - an overview for stakeholders, the public and the NHS (third edition) 25 April 2007 The guideline development process - an overview for stakeholders, the public and the NHS 07 May 2004

This page was last updated: 30 March 2010